FY2025 EPS Estimates for Certara Lifted by Leerink Partnrs

Certara, Inc. (NASDAQ:CERT - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Certara in a research report issued to clients and investors on Monday, April 14th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.29 per share for the year, up from their prior estimate of $0.27. The consensus estimate for Certara's current full-year earnings is $0.28 per share.

Several other brokerages also recently weighed in on CERT. TD Cowen assumed coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective for the company. Robert W. Baird upped their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Barclays decreased their price target on Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. William Blair restated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Finally, Stephens restated an "overweight" rating and set a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.17.

Certara Stock Performance

Shares of CERT stock traded up $0.62 during midday trading on Thursday, hitting $14.15. 2,114,112 shares of the company were exchanged, compared to its average volume of 1,188,632. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a market capitalization of $2.28 billion, a P/E ratio of -70.75, a PEG ratio of 9.29 and a beta of 1.64. The firm's 50 day moving average price is $11.62 and its two-hundred day moving average price is $11.46. Certara has a 52 week low of $8.64 and a 52 week high of $17.94.

Institutional Trading of Certara

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CERT. ArrowMark Colorado Holdings LLC lifted its stake in Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after purchasing an additional 3,861,674 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Certara by 864.0% in the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock valued at $40,253,000 after purchasing an additional 3,387,590 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Certara in the 4th quarter valued at about $17,852,000. Brown Brothers Harriman & Co. increased its stake in Certara by 63.8% in the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock valued at $40,668,000 after purchasing an additional 1,487,998 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Certara by 169.0% in the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock valued at $21,248,000 after buying an additional 1,253,385 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.